- Home
- » Tags
- » Basiliximab
Top View
- 4 Chimeric and Humanized Antibodies Have a Longer Circulating Half-Life and Reduced Immunogenicity [Adair, F 2002]. 1.5 Objectiv
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- REALLY ESSENTIAL MEDICAL IMMUNOLOGY Arthur Rabson, Ivan M.Roitt, Peter J
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- And Biomarker-Based Algorithm for Management of Acute Gvhd
- Long-Term Follow-Up of Corticosteroid Refractory Acute GVHD Treated with an Inolimomab-Based Algorithm: a Single Center Experience
- Medication Guidelines for Solid Organ Transplants
- Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
- Vaccination in Immunocompromised Patients ´Biologicals´
- Simulect® (Basiliximab)
- Immunology; an Illustrated Outline; Sixth Edition
- Provider Procedures Manual January 2019 Provider Handbooks
- Appendix A: Dosing Regimens Modelled
- Simulect, INN- Basiliximab
- Structural Basis of Immunosuppression by the Therapeutic Antibody Daclizumab
- Antivirals for Herpes Simplex Virus
- Hypersensitivity Reactions to Biological Drugs M Corominas,1 G Gastaminza,2 T Lobera3
- The Immunology of Solid Organ Transplantation
- Tocilizumab), Human Igg1 Antibody
- Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-Mediated Rejection in Kidney Transplant Recipients
- Simulect, INN-Basiliximab
- Basiliximab (Simulect)
- 2020 Table of Drugs
- Infliximab Combination for the Treatment of Severe Gastrointestinal Acute Gvhd
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Transplant Immunology 101 Immunosuppressive Therapies Infectious Prophylaxis Immunosuppressive Pharmacotherapy Management Key Issues
- Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
- Standard Induction with Basiliximab Versus No Induction in Low Immunological Risk Kidney Transplant Recipients
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Basiliximab Vs. Limited-Dose Daclizumab (2 Mg/Kg) Administered in Single Or Two Separated Doses in Kidney Transplantation†
- (INN) for Biological and Biotechnological Substances
- Pharmaceutical Appendix to the Tariff Schedule 2
- Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity
- Monoclonal Antibodies – Addressing the Challenges on the Manufacturing Processing of an Advanced Class of Therapeutic Agents
- Do Not Tube List
- Thalidomide - Wikipedia, the Free Encyclopedia
- Mediated Rejection; Histological Improvement, Reduction of Proteinuria and Renal Function Stabilization
- Kidney Transplantation and COVID-19
- Guideline 280FM Management of Patients on Immunosuppressants Admitted with Suspected
- Cytokines in Graft-Versus-Host Disease Andrea S
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Pathophysiology, Prevention, and Treatment of Acute Graft-Versus-Host Disease
- Hypersensitivity Reactions to Biologics (Part I)